Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

被引：0

作者：

Qiu, Lugui ^{[1
,2
]}

Fu, Weijun ^{[3
]}

Xia, Zhongjun ^{[4
]}

Fu, Zhengzheng ^{[5
]}

Chen, Wenming ^{[6
]}

Chang, Chunkang ^{[7
]}

Fang, Baijun ^{[8
]}

An, Gang ^{[1
,2
]}

Wei, Yongqiang ^{[9
]}

Cai, Zhen ^{[10
]}

Gao, Sujun ^{[11
]}

Weng, Jianyu ^{[12
]}

Chen, Lijuan ^{[13
]}

Jing, Hongmei ^{[14
]}

Fei, Li ^{[15
]}

Liu, Zhuogang ^{[16
]}

Chen, Xiequn ^{[17
]}

Liu, Jing ^{[18
]}

Yu, Yang ^{[19
]}

Wang, Aihua ^{[19
]}

Yang, Yijun ^{[19
]}

Yu, Zhinuan ^{[19
]}

Lynch, Kevin ^{[19
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China

[3] Shanghai Chang Zheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Dept Hematol Oncol, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, Guangzhou, Peoples R China

[5] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China

[6] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China

[7] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China

[8] Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[9] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China

[10] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Bone Marrow Transplantat Ctr,Dept Hematol, Hangzhou, Zhejiang, Peoples R China

[11] Jilin Univ, Hosp 1, Dept Hematol, Changchun, Peoples R China

[12] Guangdong Gen Hosp, Guangzhou, Peoples R China

[13] Nanjing Med Univ, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China

[14] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[15] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China

[16] China Med Univ, Shengjing Hosp, Shenyang, Peoples R China

[17] Air Force Med Univ, Xijing Hosp, Xian, Peoples R China

[18] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China

[19] Antengene Therapeut Ltd, Shanghai, Peoples R China

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145282

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4770

引用

页数：5

共 50 条

[1] Phase 2 MARCH study: ATG-010 plus Dexamethasone in Chinese relapsed/refractory Multiple Myeloma (RRMM) patients previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI)
Qiu, Lugui
Fu, Weijun
Fu, Chengcheng
Chen, Wenming
Chang, Chunkang
Fang, Baijun
An, Gang
Wei, Yongqiang
Cai, Zhen
Gao, Sujun
Weng, Jianyu
Chen, Lijun
Jing, Hongmei
Li, Fei
Liu, Zhuogang
Chen, Xiequn
Liu, Jing
Li, Ling
Yu, Yang
Wang, Aihua
Yang, Yijun
Yu, Zhinuan
Xia, Zhongjun
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S155 - S156
[2] Results of the phase 2 MARCH Study: Oral ATG-010 (Selinexor) plus low dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma (RRMM) previously treated with an immunomodulatory agent (IMiD) and a proteasome inhibitor (PI).
Fu, Weijun
Xia, Zhongjun
Fu, Chengcheng
Chen, Wenming
An, Gang
Cai, Zhen
Fang, Baijun
Jing, Hongmei
Wei, Yongqiang
Weng, Jianyu
Chang, Chunkang
Chen, Lijuan
Gao, Sujun
Chen, Xiequn
Li, Fei
Liu, Zhuogang
Liu, Jing
Jiao, Ying
Wang, Aihua
Qiu, Lugui
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[3] Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Lugui Qiu
Zhongjun Xia
Chengcheng Fu
Wenming Chen
Chunkang Chang
Baijun Fang
Gang An
Yongqiang Wei
Zhen Cai
Sujun Gao
Jianyu Weng
Lijuan Chen
Hongmei Jing
Fei Li
Zhuogang Liu
Xiequn Chen
Jing Liu
Aihua Wang
Yang Yu
Wenxi Xiang
Kevin Lynch
Zhinuan Yu
Weijun Fu
BMC Medicine, 20
[4] Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Qiu, Lugui
Xia, Zhongjun
Fu, Chengcheng
Chen, Wenming
Chang, Chunkang
Fang, Baijun
An, Gang
Wei, Yongqiang
Cai, Zhen
Gao, Sujun
Weng, Jianyu
Chen, Lijuan
Jing, Hongmei
Li, Fei
Liu, Zhuogang
Chen, Xiequn
Liu, Jing
Wang, Aihua
Yu, Yang
Xiang, Wenxi
Lynch, Kevin
Yu, Zhinuan
Fu, Weijun
BMC MEDICINE, 2022, 20 (01)
[5] ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)
Fu, Weijun
Qiu, Lugui
Xia, Zhongjun
Fu, Zhengzheng
Chen, Wenming
Chang, Chunkang
Fang, Baijun
An, Gang
Wei, Yongqiang
Cai, Zhen
Gao, Sujun
Weng, Jianyu
Chen, Lijuan
Jing, Hongmei
Fei, Li
Liu, Zhuogang
Chen, Xiequn
Liu, Jing
Yu, Yang
Wang, Aihua
Yu, Zhinuan
Yang, Yijun
Lynch, Kevin
BLOOD, 2021, 138
[6] ANCHOR (OP-104) Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI): Phase 1 Update
Pour, Ludek
Efebera, Yvonne A.
Granell, Miquel
Hajek, Roman
Oriol, Albert
Delaunay, Jacques
Le Du, Katell
Eveillard, Jean-Richard
Karlin, Lionel
Maisnar, Vladimir
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Norkin, Maxim
Ribrag, Vincent
Richardson, Paul G.
Straub, Jan
Byrne, Catriona
Jacques, Christian
Sydvander, Malin
Ocio, Enrique
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S326 - S327
[7] y ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)
Ocio, Enrique M.
Efebera, Yvonne A.
Granell, Miquel
Hajek, Roman
Maisnar, Vladimir
Karlin, Lionel
Mateos, Maria-Victoria
Richardson, Paul G.
Oriol, Albert
Norin, Stefan
Sydvander, Malin
Obermuller, Jakob
Pour, Ludek
BLOOD, 2019, 134
[8] Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (Pi) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed
Siegel, David
Schiller, Gary J.
Song, Kevin W.
Agajanian, Richy
Stockerl-Goldstein, Ketih
Kaya, Hakan
Sebag, Michael
Samaras, Christy
Malek, Ehsan
Talamo, Giampaolo
Seet, Christopher S.
Mouro, Jorge
Zafar, Faiza
Chung, Weiyuan
Srinivasan, Shankar
Qian, Max
Agarwal, Amit
Thakurta, Anjan
Bahlis, Nizar J.
BLOOD, 2017, 130
[9] Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)
Pour, Ludk
Efebera, Yvonne A.
Granell, Miquel
Hajek, Roman
Oriol, Albert
Delaunay, Jacques
Le Du, Katell
Eveillard, Jean-Richard
Karlin, Lionel
Maisnar, Vladimir
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Norkin, Maxim
Ribrag, Vincent
Richardson, Paul G.
Staub, Jan
Byrne, Catriona
Sydvander, Malin
Ocio, Enrique M.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S23 - S24
[10] ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Up-dated Efficacy and Safety
Ocio, Enrique M.
Efebera, Yvonne A.
Hajek, Roman
Granell, Miquel
Maisnar, Vladimir
Straub, Jan
Eveillard, Jean-Richard
Karlin, Lionel
Ribrag, Vincent
Mateos, Maria-Victoria
Oriol, Albert
Sydvander, Malin
Norin, Stefan
Mannikko, Sofia
Pour, Ludek
BLOOD, 2020, 136

← 1 2 3 4 5 →